SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention amid a volatile sector-wide biotech pullback and rebound, with traders debating whether the recent bounce signals stabilization or whether weakness will persist. The discussion links biotechs swings to rising-rate and risk-off concerns, while some see lower rates, sector rotation and M&A activity as potential supports.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is attracting attention ahead of its quarterly results, with traders debating whether weak branded-checkout trends and margin pressure could renew the stocks pattern of post-earnings declines, or whether subdued expectations and growth in Venmo and advertising could support a rebound. Takeover and bank-charter speculation also appears, but remains unconfirmed.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETRs sharp rebound has fueled short-squeeze and options-related speculation, with traders pointing to the companys share repurchases, a small float, and elevated short interest as potential pressure points. The squeeze is unconfirmed, and some traders question whether the rally can continue without stronger volume or further turnaround progress.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A rebound in Nasdaq and AI-linked tech after a sharp selloff has drawn attention to TQQQ, with traders split between viewing the move as a relief bounce with room to continue and warning it may be a bull trap. The funds 3x leverage amplifies the swings, fueling active options and technical trading amid uncertainty around the Fed and upcoming earnings.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos prolonged share-price slide is fueling concern about Eli Lillys competitive gains in the GLP-1 market and skepticism about managements execution and pipeline. Traders are split on whether recent licensing deals and oral Wegovy demand can support a recovery, with critics arguing the deals are too early-stage to address the competitive gap.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas quarterly earnings and outlook are driving discussion: despite a better-than-expected quarter and resilient payment volumes, traders focused on cautious growth guidance, higher expenses and workforce cuts as reasons for the muted reaction. Some see the results as evidence of a durable payments business, while others argue the beat was priced in and margins are under pressure.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee joined Irth Capitals effort to take the company private are driving attention, reviving speculation about a potential sale. Traders are split between viewing the bid as a possible catalyst and doubting a deal will close, amid criticism of the board and concerns about weak sales and the turnaround.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new share-repurchase authorization were overshadowed by a narrowed full-year profit outlook, prompting a sharp selloff. Traders are split between viewing the decline as an overreaction given the cash-flow outlook and buyback, and seeing the guidance as a reason for caution.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Anticipation of Eli Lillys Q3 report is driving attention, with traders focused on whether Mounjaro and Zepbound demand can sustain growth and support the stocks run near record highs. Bulls point to Lillys strength in obesity drugs, while skeptics question whether expectations are too high and cite competition from Novo and the oral GLP-1 market.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Mixed Nielsen and scanner-sales reportsparticularly concerns about the core Celsius brand despite Alani Nu strengthare driving debate around growth and upcoming earnings. Bulls point to Alani Nu and expansion potential, while bears focus on core-brand weakness, competition and management execution; Pepsi buyout talk remains speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?

BAX's Q3 revenues may rise, but earnings may fall amid tariffs, manufacturing costs and infusion pump challenges. Will stronger demand offset pressures?

Fox Moves Up In Market Cap Rank, Passing Baxter International

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Fox Corp (Symbol: FOXA) has taken over the #451 spot from Baxter International Inc (Symbol: BAX), according to The Online Investor.

 Market capitalization is an import...

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link...

Are Investors Undervaluing Baxter International (BAX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?

Here is how Baxter International (BAX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Baxter Releases Inaugural Connected Hospital Report

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the release of its 2026 Connected Hospital Report, offering new insights into how hospitals across the United States are leveraging technology investments to drive clinical and operational outcomes. Based on a survey of...

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Here's Why You Should Retain Baxter Stock in Your Portfolio for Now

BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.

BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure

Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment sells connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment focuses on the sales of specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Baxter International Inc.

Baxter Stock Logs Worst Day In 3 Months On Margin Pain And Weak Guidance — Retail Sees Long-Term Buy Opportunity

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Baxter’s Q3 profit rose 41% year-over-year, but gross margin plunged 430 basis points to 39.4% amid higher manufacturing costs and weak IV solution demand.</li><li>The company cut its 2025 EPS and sales forecasts and announced a dividend reduction starting January 2026 to accelerate debt repayment.</li><li>Shipment delays for its Novum infusion pump and continued fluid conservation in U.S. hospitals are expected to weigh on near-term performance.</li></ul>Shares of Baxter International Inc. fell sharply on Thursday, logging their worst session in three months, after the medical products company’s upbeat profit performance was outweighed by weaker margins, reduced guidance, and lingering operational challenges.The stock plunged 14.5% to $19.16 on Thursday, before recovering 1.6% in after-hours trading.<h2 class="st-heading-2">Margins Sink Despite Strong Earnings</h2>For the third quarter (Q3), Baxter reported $2.8 billion in sales, up 5% year-over-year, and an adjusted EPS of $0.69, a 41% increase from last year, marking its highest quarterly profit since 2022.However, the improvement was driven primarily by one-time benefits including temporary service agreement (TSA) income and cost discipline, while underlying operational momentum remained sluggish.The company’s gross margin plunged 430 basis points to 39.4%, hit by product mix shifts, lower IV solution volumes, and higher manufacturing costs. Operating margin also narrowed, forcing Baxter to cut full-year guidance for both revenue and earnings.<h2 class="st-heading-2">Infusion Pump Delays And Weak Hospital Demand&nbsp;</h2>Sales from Infusion Therapies and Technologies (ITT) fell 4% operationally, due to ongoing shipment holds for the Novum IQ Large Volume Pump (LVP),&nbsp; an issue the company now expects to extend beyond 2025 because of unresolved flow rate problems.Meanwhile, demand for IV solutions in U.S. hospitals remained soft as health systems continued fluid-conservation measures following Hurricane Helene, delaying recovery in one of Baxter’s core markets.The company also cited tariff costs of about $40 million this year and supply chain inefficiencies from lower production volumes as additional drags on profitability.<h2 class="st-heading-2">Dividend Cut And Guidance Reduction&nbsp;</h2>Baxter said it would slash its quarterly dividend to $0.01 per share starting January 2026, freeing up over $300 million in annual cash flow to pay down debt. It aims to bring net leverage down to 3x by the end of 2026, before resuming more aggressive capital deployment.The company lowered its 2025 adjusted EPS outlook to $2.35–$2.40 (from $2.42–$2.52 previously) and trimmed its full-year sales growth target to 4%–5% reported, or just 1%–2% operationally.Fourth-quarter guidance also disappointed, with EPS projected between $0.52 and $0.57, reflecting continued volume softness and margin pressure.<h2 class="st-heading-2">New CEO Faces Challenge Of Stabilizing Operations</h2>Newly appointed CEO Andrew Hider said the focus is on stabilizing the business, strengthening the balance sheet, and embedding a “continuous improvement” culture through a new internal program called Baxter GPS (Growth and Performance System).Hider acknowledged the near-term headwinds but maintained that the company’s diversified hospital product portfolio and cash flow discipline position it well for recovery.<h2 class="st-heading-2">Baxter Draws Wave Of Optimism On Stocktwits</h2>On Stocktwits, retail sentiment for Baxter was ‘extremely bullish’ amid a 2,100% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:970/147;" src="https://news.stocktwits-cdn.com/bax_ss_jpg_2c6bbe4b2a.webp" alt="bax ss.jpg" width="970" height="147"><figcaption>BAX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>One user said they had started a position below $20 and saw it as an easy long-term hold.<stembedurl>https://stocktwits.com/thalkdoi/message/634381485</stembedurl>Another user argued the stock was undervalued given Baxter’s long history and dominant role in U.S. healthcare, suggesting it remained a strong candidate for long-term gains.<stembedurl>https://stocktwits.com/SpaceForceOne/message/634337975</stembedurl><a href="https://stocktwits.com/symbol/BAX">Baxter’s stock</a> has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Baxter International logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The company cut its 2025 EPS and sales forecasts and announced a dividend reduction starting January 2026 to accelerate debt repayment.

Track BAX stock price, charts, news and real-time market activity on Stocktwits. Join the BAX message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Baxter International Inc stock.

BAX Stock Price Today - Baxter International Inc News, Charts, Retail Sentiment

$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$25.29
Prev Close	$25.30
Open	$25.62
Dividend Yield	2.72%
50-Day Moving Average	$24.74
Beta	0.85
Avg. Volume	6.76M
PE Ratio	-13.12

52-Week High	$30.00
52-Week Low	$15.73
Market Capitalization	$13.08B
EPS (Annual)	-$2.05
Price to Book	2.11
Revenue Per Employee	$299,840.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BAX Fundamentals